Lantheus Holdings, Inc. (NASDAQ:LNTH) Short Interest Down 20.0% in December

Lantheus Holdings, Inc. (NASDAQ:LNTH) saw a significant drop in short interest during the month of December. As of December 31st, there was short interest totaling 5,728,234 shares, a drop of 20.0% from the December 15th total of 7,157,474 shares. Approximately 8.8% of the company’s shares are sold short. Based on an average daily trading volume, of 1,043,463 shares, the days-to-cover ratio is currently 5.5 days. Based on an average daily trading volume, of 1,043,463 shares, the days-to-cover ratio is currently 5.5 days. Approximately 8.8% of the company’s shares are sold short.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in LNTH. Vanguard Group Inc. lifted its position in shares of Lantheus by 1.7% in the 3rd quarter. Vanguard Group Inc. now owns 6,952,418 shares of the medical equipment provider’s stock worth $356,590,000 after purchasing an additional 115,338 shares during the period. Assenagon Asset Management S.A. bought a new position in Lantheus in the third quarter worth approximately $65,654,000. TD Asset Management Inc lifted its holdings in Lantheus by 25.0% during the third quarter. TD Asset Management Inc now owns 790,950 shares of the medical equipment provider’s stock worth $40,568,000 after buying an additional 158,358 shares during the period. Polaris Capital Management LLC purchased a new stake in Lantheus during the third quarter worth $32,687,000. Finally, Boston Partners increased its holdings in shares of Lantheus by 30.5% in the 2nd quarter. Boston Partners now owns 576,362 shares of the medical equipment provider’s stock valued at $46,432,000 after acquiring an additional 134,781 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Trading Down 1.8%

Shares of Lantheus stock traded down $1.17 on Monday, hitting $64.25. 737,897 shares of the company traded hands, compared to its average volume of 862,117. The company has a current ratio of 2.67, a quick ratio of 2.49 and a debt-to-equity ratio of 0.51. The company has a market cap of $4.26 billion, a PE ratio of 27.00 and a beta of -0.11. The stock’s 50 day moving average price is $62.19 and its 200-day moving average price is $60.76. Lantheus has a 52 week low of $47.25 and a 52 week high of $111.29.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, November 6th. The medical equipment provider reported $1.27 EPS for the quarter, hitting the consensus estimate of $1.27. Lantheus had a return on equity of 30.88% and a net margin of 10.99%.The company had revenue of $384.01 million for the quarter, compared to the consensus estimate of $363.42 million. During the same period last year, the business posted $1.70 EPS. Lantheus’s quarterly revenue was up 1.4% on a year-over-year basis. Lantheus has set its FY 2025 guidance at 5.500-5.650 EPS. Equities research analysts predict that Lantheus will post 6.01 EPS for the current year.

Wall Street Analysts Forecast Growth

LNTH has been the topic of a number of analyst reports. The Goldman Sachs Group set a $77.00 price objective on shares of Lantheus and gave the company a “neutral” rating in a research report on Wednesday, October 8th. Mizuho lifted their price target on shares of Lantheus from $60.00 to $72.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. Truist Financial increased their price objective on shares of Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. Finally, Weiss Ratings raised shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 6th. Five analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $78.00.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.